Literature DB >> 8077922

Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding.

S Daenke1, H J Schramm, C R Bangham.   

Abstract

Human T cell leukaemia virus type 1 (HTLV-1) protease (PR14) was expressed in bacteria and purified by gel filtration. A continuous spectrophotometric assay was used to measure the kinetic parameters of substrate hydrolysis by PR14. Several peptide substrates containing HTLV-1 sequences known to be cleaved by PR14 were used. Cleavage analysis showed that the affinity with which PR14 binds these substrates is higher than that previously reported for HTLV-1 Gag peptides. Also, the affinities of peptides containing the sites involved in autocleavage of protease from its precursor are higher than for the peptides containing sites required for structural protein maturation. This suggests that the autocatalysis of protease from its own precursor has priority over other cleavage reactions and supports similar observations of an ordered hierarchy of processing events by retroviral proteases. As the N- and C-terminal regions of retroviral aspartic proteases are known to contribute to stability of the dimer by forming antiparallel beta-strands, short peptides corresponding to these terminal sequences of HTLV-1 protease were tested for their ability to inhibit cleavage of substrates by PR14. Inhibition was seen with a C-terminal peptide corresponding exactly to the C-terminal 11 amino acids of the processed PR14, whereas a peptide containing a sequence situated further from the C terminus was less effective. An inhibitor of the protease of human immunodeficiency virus type 1, Ro 31-8959, was found to be a poor inhibitor of PR14.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077922     DOI: 10.1099/0022-1317-75-9-2233

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  African origin of human T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtype in Congolese Bambuti Efe Pygmies.

Authors:  A M Vandamme; M Salemi; M Van Brussel; H F Liu; K Van Laethem; M Van Ranst; L Michels; J Desmyter; P Goubau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  A novel protease processing site in the transframe protein of human T-cell leukemia virus type 1 PR76(gag-pro) defines the N terminus of RT.

Authors:  Gisela Heidecker; Shawn Hill; Patricia A Lloyd; David Derse
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease.

Authors:  Y S Ding; S M Owen; R B Lal; R A Ikeda
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Structure of equine infectious anemia virus proteinase complexed with an inhibitor.

Authors:  A Gustchina; J Kervinen; D J Powell; A Zdanov; J Kay; A Wlodawer
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

5.  Human T-cell leukemia virus type 1 reverse transcriptase (RT) originates from the pro and pol open reading frames and requires the presence of RT-RNase H (RH) and RT-RH-integrase proteins for its activity.

Authors:  B Trentin; N Rebeyrotte; R Z Mamoun
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

6.  C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.

Authors:  János Kádas; Péter Boross; Irene T Weber; Péter Bagossi; Krisztina Matúz; József Tözsér
Journal:  Biochem J       Date:  2008-12-15       Impact factor: 3.857

7.  The Effects of Side-Chain Configurations of a Retro-Inverso-Type Inhibitor on the Human T-Cell Leukemia Virus (HTLV)-1 Protease.

Authors:  Chiyuki Awahara; Daiki Oku; Saki Furuta; Kazuya Kobayashi; Kenta Teruya; Kenichi Akaji; Yasunao Hattori
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.